21% OFF Orforglipron – 12mg × 100 tablets (Research Use Only)
Orforglipron, a non-peptide small-molecule GLP-1 receptor agonist studied in GLP-1 receptor pharmacology. Supplied for laboratory research and identification purposes only.
Availability: In stock
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.
Research Disclaimer: All products currently listed on this site are for research purposes only.
Overview
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist, representing a major structural departure from the injectable peptide-based GLP-1 agonist class. Unlike semaglutide and other peptide GLP-1 agonists, orforglipron’s non-peptide structure enables oral bioavailability without albumin-binding modifications. This mechanistic distinction has made orforglipron a subject of intense comparative pharmacology research interest, particularly in receptor activation kinetics, downstream signaling profiles, and tissue distribution studies.
What It Is
Orforglipron (LY3502970) is a synthetic small-molecule GLP-1 receptor agonist with a non-peptide core scaffold. As a non-peptide agonist, orforglipron engages the GLP-1 receptor transmembrane binding domain rather than the extracellular peptide recognition domain used by peptide GLP-1 agonists — a distinction relevant to allosteric and orthosteric receptor pharmacology research.
Key Research Applications
- Non-peptide GLP-1 receptor activation, binding mode, and downstream signaling research
- Comparative pharmacology vs. peptide GLP-1 agonists (semaglutide, liraglutide) in receptor studies
- Oral small-molecule receptor agonist pharmacokinetics and bioavailability research
- GLP-1 receptor orthosteric vs. allosteric binding site characterization studies
- Insulin secretion, glucagon suppression, and gastric emptying research models
- CNS GLP-1 receptor satiety pathway and hypothalamic activation research
- Comparative metabolic endpoint studies (peptide vs. non-peptide GLP-1R agonists)
- Phase III clinical pharmacology reference data support for receptor biology research
Technical Specifications
| Compound | Orforglipron (LY3502970) |
| Mechanism | Non-Peptide GLP-1 Receptor Agonist |
| Developer | Eli Lilly |
| Purity | ≥98% (supplier specification) |
| Form | Oral tablet (12mg) |
| Quantity | 100 tablets per bottle |
| Oral Bioavailability | Yes (non-peptide structure) |
| Storage | Room temperature, away from moisture and light |
FOR RESEARCH USE ONLY. Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.
Not sure which compounds fit your research? Browse the Research Hub →
- Processing: Orders ship within 1–2 business days
- Domestic delivery: 3–5 business days via USPS Priority / UPS Ground
- Free shipping on orders over $100
- Temperature handling: Cold-chain packaging available on request for lyophilized peptides
- Tracking: Emailed automatically at time of dispatch
- Store in a cool, dry place away from heat, moisture and direct light
- Keep the container tightly closed
Pairs Well With
Related research products
Reviews
There are no reviews yet.